Breast cancer drug may hold key to tackling most deadly type of melanoma

Breast cancer drug may hold key to tackling most deadly type of melanoma

23 July 2019

Barbara Holland tried everything to stop headaches for months before her doctor sent her for an MRI. Her scans showed a tumour in her sinus passages, and four tumours in her brain. In August 2015, she was diagnosed with mucosal melanoma.

Mucosal melanoma, which occurs on the inner surfaces of the body such as the mouth, nose and anogenital region and is not linked to UV exposure, has a very poor prognosis with less than 20% of patients surviving five years after diagnosis.

Now, an Australian-led international team of researchers has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating this aggressive and deadly form of melanoma.

The international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has uncovered the diverse genetic drivers for mucosal melanoma as well as identified potential treatments.

Lead study author Professor Richard Scolyer, Co-Medical Director Melanoma Institute Australia, The University of Sydney and Royal Prince Alfred Hospital says the study allowed researchers to not only look for new drug targets, but to also match available targeted drugs to the specific genetic drivers in mucosal melanoma.

“We now understand the genetic drivers of mucosal melanoma, and can match those to potential treatments,” Professor Scolyer said. The study revealed that a currently available class of drug commonly used to treat breast cancer looks promising for treating mucosal melanoma.

“The ramifications of this study are immense and are critical in us reaching our goal of zero deaths from melanoma.”

Published online at Nature Communications, the study detailed the genetic analysis of 67 mucosal melanoma tumours from patients from Australia, China, the United States and Europe. Using both whole-genome sequencing and whole-exome sequencing, the authors identified diverse drivers that suggested that mucosal melanoma has potential therapeutic targets.

The majority of mucosal melanomas sequenced in the study showed potential susceptibility to currently available classes of drug. One in particular, CDK4/6 inhibitors, are a class of drug used to treat HR-positive, HER2-negative breast cancer.

“While advancements in treatment have drastically improved survival outcomes for cutaneous (or skin) melanoma patients, those treatments do not work as well for mucosal melanoma patients,” Professor Scolyer added.

“But now we can build our treatment arsenal for this group of patients – starting with CDK4/6 inhibitors used to treat a subtype of breast cancer.”

The study also found possible reasons why mucosal melanoma is less responsive to immunotherapy which has had such success in saving the lives of UV-related melanoma patients. It revealed that a mutation in some mucosal melanomas locks immune cells out of the tumour, rendering immunotherapy treatment ineffective.

“I’m one of the lucky ones,” said Barbara.

The tumour in her sinuses was removed with surgery, and after three years of immunotherapy, one of her brain tumours is no longer measurable and the others are stable.

“This news is so exciting for other mucosal patients and their families. Hopefully in the near future, they will be able to have the same positivity that I have.”

While rare in Western populations like in Australia, where it makes up less than 2% of all melanoma cases, mucosal melanoma makes up a third of all melanoma cases worldwide.

A previous study also coming from the Australian Melanoma Genome Project found that mucosal melanoma is not linked to UV radiation, as is the case with cutaneous (or skin) melanoma.

There are no known risk factors for mucosal melanoma, making prevention strategies difficult. It is also usually diagnosed at a later stage of disease due to the challenges of monitoring sites where it is found – the internal surfaces of the body.

“The next exciting step is for Melanoma Institute Australia to develop a clinical trial to test classes of drugs and their effectiveness for treating mucosal melanoma,” said study author Professor Georgina Long, Co-Medical Director Melanoma Institute Australia The University of Sydney and Royal North Shore Hospital

“This is the new frontier in melanoma treatment, with very real benefits for patients internationally, and we are proud to be leading the world in saving lives.”

Barbara is no longer on treatment and comes to MIA for three monthly scans.

“It’s amazing to know that there could soon be new treatments for this horrible disease. I think the best part about this discovery is that it gives hope,” said Barbara.

MIA joins Sydney Health Partners
22 Dec 2021

MIA joins Sydney Health Partners

Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.

Tags: melanoma
Congratulations Dr Hansol Lee
22 Dec 2021

Congratulations Dr Hansol Lee

Promising young MIA researcher conferred with University of Sydney PhD.

Tags: melanoma
Olympians join forces for melanoma warning
13 Dec 2021

Olympians join forces for melanoma warning

Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach

Tags: melanoma
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
07 Dec 2021

MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'

Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.

Tags: melanoma
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
06 Dec 2021

Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award

Honouring the exceptional impact of his work on communities around the world.

Tags: melanoma
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
03 Dec 2021

MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research

Awarded for their life-saving discoveries transforming melanoma patient care.

Tags: melanoma
Aussies urged to mark start of summer by checking their skin
01 Dec 2021

Aussies urged to mark start of summer by checking their skin

National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment

Tags: melanoma
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
24 Nov 2021

Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research

Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.

Tags: melanoma
AMC2021 conference wrap-up
23 Nov 2021

AMC2021 conference wrap-up

Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.

Tags: melanoma
Journalist and news reader Peter Overton our new National Ambassador
23 Nov 2021

Journalist and news reader Peter Overton our new National Ambassador

Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
19 Nov 2021

MIA researchers feature on prestigious Highly Cited Researchers 2021 List

MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.

Tags: melanoma
New research into importance of skin surveillance to save lives from melanoma
04 Nov 2021

New research into importance of skin surveillance to save lives from melanoma

New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.

Tags: melanoma
Game On Mole - saving lives this summer
31 Oct 2021

Game On Mole - saving lives this summer

With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever. 

Tags: melanoma
Melanoma March physical events in 2022
22 Oct 2021

Melanoma March physical events in 2022

We are excited to announce a return to our much-loved physical Melanoma March events in March 2022! 

Tags: melanoma
Community Fundraising Wrap Up July-Sept 2021
15 Oct 2021

Community Fundraising Wrap Up July-Sept 2021

Read more about the wonderful MIA community fundraising initiatives held recently.

Tags: melanoma
Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Melanoma Bike Bash 2021: What a ride!
20 Sep 2021

Melanoma Bike Bash 2021: What a ride!

Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
MIA researchers awarded $7.2m in NHMRC grants for health research
15 Sep 2021

MIA researchers awarded $7.2m in NHMRC grants for health research

Three MIA researchers at University of Sydney received grants to further their important melanoma research.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.